Galenicum Health obtains the bioequivalence studies for Sitagliptin/Metformin combination

February 16, 2018

During the month of January, Galenicum Health received the bioequivalence studies of Sitagliptin/Metformin with a positive result.

This new combination is one of the most innovative drugs indicated for the treatment of diabetes with the potential advantage of administering fewer oral forms in each shot.

Galenicum expands the portfolio in this key therapeutic area for the company in the future. In 2017, Galenicum already obtained the bioequivalence studies of Sitagliptin monotherapy and Vildagliptin monotherapy.